releases: https://calvert.house.gov/media/press-releases/rep-calvert-applauds-senate-passage-act-als-reauthorization-act
Data license: MIT · Data source: dwillis/congress-press
This data as json
| url | title | date | year | month | party | chamber | state | member_name | bioguide_id | domain | scraper | source | date_source | text | has_text | collected_at | updated_at |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| https://calvert.house.gov/media/press-releases/rep-calvert-applauds-senate-passage-act-als-reauthorization-act | Rep. Calvert Applauds Senate Passage of the ACT for ALS Reauthorization Act | 2026-09-29 | 2026 | 2026-09 | Republican | House | CA | Ken Calvert | C000059 | calvert.house.gov | calvert | https://calvert.house.gov/media/press-releases | scraper | Today, Congressman Ken Calvert (CA-41) praised the Senate passage of the ACT for ALS Reauthorization Act, H.R. 8205. Rep. Calvert is the Republican lead cosponsor of the bill and serves as a Co-Chair of the House ALS Caucus. The bill reauthorizes programs that support research and development of drugs and other therapies to address ALS. Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease, is a progressive, fatal neurological disease. The bill was approved by the House of Representatives on July 22, 2026, and will now head to the White House for the President’s signature. H.R. 8205 was introduced by Rep. Mike Quigley (IL-05) with Rep. Calvert as the lead Republican cosponsor. Companion legislation was introduced in the Senate by Senator Lisa Murkowski (AK) and Senator Chris Coons (CT). “The passage of the ACT for ALS Reauthorization Act is a renewal of Congress’s commitment to finding cures and treatments for ALS,” said Rep. Calvert. “As a Co-Chair of the bipartisan ALS Caucus, I know just how hard those impacted by ALS have worked to get this bill across the finish line and I applaud their tireless advocacy. As anyone in the ALS community knows, tough days lie ahead, but the passage of the ACT for ALS Reauthorization is a good day full of hope and a pledge to stand together to fight this terrible disease.” “Since 2021, the ACT for ALS has helped thousands of Americans access the promising treatments and research they need,” said Rep. Quigley (IL-05). “But there is still no cure for ALS, making it a 100% fatal disease. We need the federal government to reauthorize the ACT for ALS immediately to continue funding ALS research. I’m proud of my colleagues in the Senate for passing this bill and continuing our work.” “For those living with ALS, every day matters. They cannot afford disruptions in research, treatment access, and support,” said Senator Murkowski. “This reauthorization ensures that the momentum we have built over the past five years will continue, keeping pathways to promising investigational treatments open while supporting the research needed to find better treatments and, ultimately, a cure. I’m grateful to Senator Coons, Representatives Quigley and Calvert, and especially the ALS community, whose persistence helped us get this legislation across the finish line before the authorization expired.” “Anyone who has known someone with ALS will tell you, it is a cruel disease that steals your mobility, your voice, and your time,” said Senator Coons. “Families deserve hope in the face of this suffering. I’m proud Senator Murkowski and I, along with Representatives Quigley and Calvert, were able to renew this bipartisan investment in hope for years to come.” “When I was diagnosed with ALS almost nine years ago, I knew that the treatment and research options available to people living with this fatal disease needed to change,” said I AM ALS co-founder Brian Wallach. “I co-authored ACT for ALS with that need for change in mind. Since its passage in 2021, federal research funding has grown to historic levels. ACT for ALS is getting us closer to a cure and is proving that ALS isn't untreatable—it's underfunded. I'm grateful to the champions in Congress and to our community of tireless advocates who ensured that this life-saving bill was renewed before it expired." “For people living with ALS and their families, final congressional passage brings us one step closer to ensuring that critical programs supporting expanded access and urgently needed research can continue,” said Sheri Strahl, MPH, MBA, President and CEO of ALS Network. “This achievement reflects the persistence of the ALS community, whose lived experiences and sustained advocacy kept this legislation moving forward. We are deeply grateful to Representatives Calvert and Quigley for listening to our community and providing the bipartisan leadership needed to carry this legislation through Congress.” "To every advocate who walked into a congressional office and wouldn't leave without a commitment: you did this,” said Calaneet Balas, President and CEO, The ALS Association. “To the families who shared their hardest moments so other families might have more time: you did this. We're grateful to our champions on both sides of the aisle who helped make this legislation possible. People living with ALS cannot wait, and neither will we.” The legislation will reauthorize ACT for ALS programs for 5 years, codify the Department of Health and Human Services’ (HHS) interpretation of Expanded Access Program eligibility guidelines, require a new FDA 5-year Action Plan, and require a new GAO report on the implementation of ACT for ALS programs in 2030. ### | 1 | 2026-10-01T11:23:28Z | 2026-10-01T11:25:15Z |